Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq
Industry
Pharmaceutical Preparations
Location
2401 4 Th Ave., Suite 1050, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 204 % -42.1%
Debt-to-equity 167 % +127%
Return On Equity -349 % -290%
Return On Assets -131 % -154%
Operating Margin -155 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.5M shares +5.08%
Common Stock, Shares, Outstanding 17.1M shares +17.9%
Entity Public Float 11M USD -38.9%
Common Stock, Value, Issued 82K USD +46.4%
Weighted Average Number of Shares Outstanding, Basic 10.5M shares +3590%
Weighted Average Number of Shares Outstanding, Diluted 10.5M shares +3590%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 13M USD +28.6%
Research and Development Expense 14.1M USD -22.6%
General and Administrative Expense 10.5M USD -12.3%
Operating Income (Loss) -24.6M USD +18.5%
Net Income (Loss) Attributable to Parent -23.7M USD -46.9%
Earnings Per Share, Basic 45.2 USD/shares +97.8%
Earnings Per Share, Diluted 45.2 USD/shares +97.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.75M USD -59.4%
Other Assets, Current 624K USD -3.85%
Assets, Current 10M USD -52.6%
Property, Plant and Equipment, Net 614K USD -39.3%
Operating Lease, Right-of-Use Asset 4.52M USD -9.46%
Other Assets, Noncurrent 68K USD -90.9%
Assets 15.1M USD -44.2%
Employee-related Liabilities, Current 922K USD -39.5%
Liabilities, Current 5.88M USD -14%
Operating Lease, Liability, Noncurrent 4.83M USD -13.8%
Other Liabilities, Noncurrent 14K USD
Liabilities 10.7M USD -13.6%
Retained Earnings (Accumulated Deficit) -241M USD -10.9%
Stockholders' Equity Attributable to Parent 4.42M USD -70%
Liabilities and Equity 15.1M USD -44.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.65M USD -246%
Net Cash Provided by (Used in) Financing Activities -1.87M USD +62.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 17.1M shares +17.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.65M USD -347%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.3M USD -30.1%
Deferred Tax Assets, Valuation Allowance 53.2M USD +8.36%
Deferred Tax Assets, Gross 54.2M USD +7.98%
Operating Lease, Liability 6.08M USD -5.9%
Lessee, Operating Lease, Liability, to be Paid 8.72M USD -11.6%
Property, Plant and Equipment, Gross 14.5M USD 0%
Operating Lease, Liability, Current 700K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.38M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.38M USD +20%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.64M USD -22.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.38M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 344K USD +199%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 106K USD -40.4%
Deferred Tax Assets, Net of Valuation Allowance 1.03M USD -8.63%
Share-based Payment Arrangement, Expense 1.5M USD -31.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%